| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., November 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the thir... |
| 05 Nov 2026 | 10-Q |
| 03 Sep 2026 |
Form 4: Schorno Dean L, EVP & Chief Financial Officer
Gave up 928 shares to cover exercise price or tax ($44.1K) · Received 4,600 shares by exercise or conversion ($99.9K) |
| 03 Sep 2026 |
Form 4: Santos David A, EVP, Chief Commercial Officer
Gave up 874 shares to cover exercise price or tax ($41.5K) |
| 03 Sep 2026 |
Form 4: Rodriguez Raul R, Director
Gave up 2,424 shares to cover exercise price or tax ($115K) |
| 03 Sep 2026 |
Form 4: Furey Raymond J., EVP, GC, CCO & Corp Sec
Gave up 877 shares to cover exercise price or tax ($41.7K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 04 Aug 2026 | S-8 |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., August 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second... |
| 04 Aug 2026 | 10-Q |
| 10 Jul 2026 |
Form 4: Hannah Alison L., EVP, Chief Medical Officer
Received 24,400 shares as a grant or award |
| 01 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company. In connection with her appointment, Dr. Hannah resigned f... |
| 24 Jun 2026 |
Form 4: Ali-Jackson Kamil, Director
Sold 2,500 shares ($87.5K) |
| 22 Jun 2026 |
Form 4: Furey Raymond J., EVP, GC, CCO & Corp Sec
Granted 7,394 Employee Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Rojkjaer Lisa, EVP, Chief Medical Officer
Granted 16,769 Employee Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Rodriguez Raul R, Director
Granted 31,700 Employee Stock Option (right to buy) |
Loading...